[HTML][HTML] Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy

J Anzengruber, M Bublin, E Bönisch, B Janesch… - Molecular …, 2017 - Elsevier
Peanut allergy is an IgE-mediated severe hypersensitivity disorder. The lack of a treatment
of this potentially fatal allergy has led to intensive research on vaccine development. Here …

Allergenic characteristics of a modified peanut allergen

N King, R Helm, JS Stanley, S Vieths… - Molecular nutrition & …, 2005 - Wiley Online Library
Attempts to treat peanut allergy using traditional methods of allergen desensitization are
accompanied by a high risk of anaphylaxis. The aim of this study was to determine if …

Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation

P Rabjohn, CM West, C Connaughton… - International archives of …, 2002 - karger.com
Background: Peanut allergy is a major health concern due to the increased prevalence,
potential severity, and chronicity of the reaction. The cDNA encoding a third peanut allergen …

Ara h 1 CD4+ T cell epitope‐based peptides: candidates for a peanut allergy therapeutic

SR Prickett, AL Voskamp, T Phan… - Clinical & …, 2013 - Wiley Online Library
Background Peanut allergy is a life‐threatening condition; there is currently no cure. While
whole allergen extracts are used for specific immunotherapy for many allergies, they can …

Characterization of the T‐cell epitopes of a major peanut allergen, Ara h 2

IN Glaspole, MP De Leon, JM Rolland, RE O'Hehir - Allergy, 2005 - Wiley Online Library
Background: The development of safe and effective immunotherapy for peanut allergy has
been complicated by the high anaphylactic potential of native peanut extracts. We sought to …

[引用][C] Ara h 1 peptide immunotherapy ameliorates peanut-induced anaphylaxis

E Simms, C Rudulier, J Wattie, WW Kwok… - Journal of Allergy and …, 2015 - jacionline.org
Methods Mice transgenic for the human leukocyte antigen DRB1* 0401 were sensitized to
peanut epicutaneously and then treated with Ara h 1 peptides. Mice were subsequently …

Targeting Ara h 2 with human‐derived monoclonal antibodies prevents peanut‐induced anaphylaxis in mice

M Paolucci, N Wuillemin, V Homère, D Bieli, A Köhli… - Allergy, 2023 - Wiley Online Library
Background Peanut allergy is a type‐I hypersensitivity immune reaction mediated by the
binding of peanut allergens to IgE‐FcεRI complexes on mast cells and basophils and by …

Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic

SR Prickett, AL Voskamp, A Dacumos-Hill… - Journal of allergy and …, 2011 - Elsevier
BACKGROUND: Peanut allergy is a life-threatening condition; there is currently no cure.
Although whole allergen extracts are used for specific immunotherapy for many allergies …

[HTML][HTML] Purification of recombinant peanut allergen Ara h 1 and comparison of IgE binding to the natural protein

BK Hurlburt, JK McBride, JB Nesbit, S Ruan, SJ Maleki - Foods, 2014 - mdpi.com
Allergic reactions to food are on the rise worldwide and there is a corresponding increase in
interest to understand the molecular mechanisms responsible. Peanut allergies are the most …

[HTML][HTML] A single monoclonal antibody against the peanut allergen Ara h 2 protects against systemic and local peanut allergy

F Storni, G Cabral-Miranda, E Roesti, L Zha… - International archives of …, 2020 - karger.com
Background: Peanut allergy is the most prevalent and dangerous food allergy. Peanuts
consist of a large number of different allergens and peanut-allergic patients are frequently …